FROM THE CEO
our Valued Shareholders:
the new CEO of Advanced Viral Research Corp., I am delighted to be
on board and am excited about the future. Although we have recently
filed our 10K with the SEC, I wanted to reach out to you - our
shareholders - in a more personal way. Our shareholders are the
backbone of our Company and we thank you for your support.
part of a new, open communications plan, I wanted to share some of
our future plans and upcoming events with you.
starting in mid-February, I have been focused on major business
initiatives and strategic direction. We remain dedicated to our
mission of introducing AVR118 to patients and are taking all of the
necessary steps to make this possible. It is my experience that a
solid strategic direction is critical to the success of any company.
To this end, I am developing a cogent and focused strategy with very
clear objectives. It is my personal commitment, as well as that of
the Company, to deliver on those objectives in a timely fashion.
you know, drug development is a long and costly endeavor that is
done under the auspices of the Food and Drug Administration (FDA) in
the United States. I have spent the last two decades in drug
development and know first-hand what it takes to get a product
approved by the FDA for marketing. The only way forward for Advanced
Viral is to remain focused on conducting high-quality clinical
trials on AVR118 in the United States in accordance with FDA
regulations. It is tantamount that we lay a solid foundation in
working with the FDA and conduct clinical trials in accordance with
Good Clinical Practices. We will also be paying a great deal of
attention to other, relevant operations which are equally important
in drug development such as quality control, quality assurance, and
is our hope that the clinical trials in Israel will help facilitate
the trials in the United States; however, it is important to point
out that any clinical trial is unpredictable and there can be no
assurances as to start date, enrollment rate and completion date.
While data cannot be disclosed on an ongoing basis due to the need
for data verification and database validation, we are encouraged by
the early findings in our Israeli trials and anticipate completion
by the end of the second quarter this year.
recognize that regular, clear and accurate communication is
essential. We have some exciting upcoming events, which include:
at ASCO: We will be presenting a poster at The American
Society of Clinical Oncology's (ASCO) 40th Annual Meeting in
June of this year. ASCO is the world's leading
professional organization representing physicians who treat
people with cancer and we are thrilled to be invited to such a
prestigious conference. As you probably are aware, any
information regarding the presentation is under embargo by ASCO
until the day of the presentation.
at an Equities Conference: We will be presenting at the
Symposium's Small Cap Equities Conference on June 2nd at the
Roosevelt Hotel in New York City.
the CEO» Sessions: I anticipate setting up a road show to
meet with investors personally in May in Boston, New York and
Florida should there be sufficient interest from our
shareholders. Please e-mail Veronica Welch at firstname.lastname@example.org
if you are interested in attending. I look forward to meeting
with as many investors as possible.
We will host an open-house event at our corporate headquarters
in Yonkers, NY in July. Please contact Maria Marino at email@example.com
for a reservation.
updates: We will be giving quarterly updates either by
conference call or by letters such as this one.
We are revamping our web site to make it more user-friendly and
informative. We will also introduce an e-mail system whereby
investors can automatically receive press releases and updates
via e-mail. An overhaul will also be done for our investor
relations and media kits.
We continue to speak with the national media on a daily basis
regarding the benefits of AVR118. This campaign will be stepped
up during the second half of the year.
a final note, the values with which I will drive the Company are
integrity and honesty. I appreciate your continued support of our
company and, most of all, thank the employees for their dedication
and tenacity. You can rest assured that we are working aggressively
to meet all of our strategic objectives. Please continue to refer to
our web site for investor updates and press releases.
S. Hawkins, PhD, MBA
President and Chief Executive Officer
The information contained herein contains forward-looking statements
that involve risks associated with clinical development, regulatory
approvals, including application to the FDA, product
commercialization and other risks described from time to time in the
SEC reports filed by the Company. AVR118 is not approved by the U.S.
Food and Drug Administration or any comparable agencies of any other
countries. There is no assurance that the Company will be able to
secure the financing necessary to complete the clinical trials of
AVR118. The Company undertakes no obligation to update or revise the
information contained in this announcement whether as a result of
new information, future events or circumstances or otherwise.